Show Stocks and Investing Publications • Thu, March 3, 2022
Tiago Fauth Maintained (ASND) at Buy with Decreased Target to $188 on, Mar 3rd, 2022
uth-maintained-asnd-at-buy-with-decreased-target-to-188-on-mar-3rd-2022.html
Stocks and Investing on Sun, Oct 27th, 2024Tiago Fauth of Credit Suisse, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Decreased Target from $196 to $188 on, Mar 3rd, 2022.
Tiago has made no other calls on ASND in the last 4 months.
There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 1 agrees with Tiago's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022
These are the ratings of the 3 analyists that currently disagree with Tiago
- David Lebowitz of "Citigroup" Initiated at Strong Buy and Held Target at $187 on, Tuesday, March 1st, 2022
- Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021